other material
confidence high
sentiment positive
materiality 0.85
Vyome reports positive Phase 2 data for VT-1953 in malignant fungating wounds; primary endpoint met
Vyome Holdings, Inc
- VT-1953 achieved significant reduction in malodor at Day 14 (p=0.002 vs baseline; p=0.0015 vs vehicle).
- Secondary endpoint met: patient-reported impact of malodor on QoL improved significantly (p=0.0256 vs vehicle).
- Exploratory endpoints showed significant pain reduction (p=0.002) and improved composite QoL at Day 14.
- No treatment-emergent adverse events or safety signals reported across the 15-patient study.
- Company filed for orphan drug designation and plans to discuss Phase 3 design with FDA.